Page last updated: 2024-12-07

triazolealanine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

triazolealanine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

triazolealanine : A non-proteinogenic alpha-amino acid that is alanine in which one of the methyl hydrogens is replaced by a 1,2,4-triazol-3-yl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID92235
CHEBI ID9675
SCHEMBL ID198638
MeSH IDM0044682

Synonyms (31)

Synonym
nsc-76227
nsc76227
10109-05-4
triazolealanine
1,2,4-triazole-3-alanine
beta-(1,2,4-triazol-3-yl)-dl-alanine
3-(4h-1,2,4-triazol-3-yl)alanine
2-amino-3-(1h-1,2,4-triazol-5-yl)propanoic acid
AC1L3NPA ,
AKOS005259492
AC1Q5S5L ,
1,2,4-triazolyl-3-alanine
alpha-amino-1h-1,2,4-triazole-3-propanoic acid
einecs 233-301-2
nsc 76227
FT-0686746
AKOS022145797
SCHEMBL198638
3-(1h-1,2,4-triazol-3-yl)alanine
CHEBI:9675
3-(1,2,4-triazol-3-yl)alanine
surecn198638
3184-54-1
dl-1,2,4-triazole-3-alanine 1-hydrate
2-amino-3-(1h-1,2,4-triazol-3-yl)propanoic acid
CS-0201658
2-amino-3-(4h-1,2,4-triazol-3-yl)propanoic acid
Q27108464
EN300-4248726
HY-W141862
mfcd00055957
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
triazolesAn azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.
non-proteinogenic alpha-amino acidAny alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (57.14)18.7374
1990's3 (42.86)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.32 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]